Corinne Ramos PhD Aliri's R&D Director and biomarker expert

Understanding drug pharmacokinetics at the tissue level, beyond systemic exposure investigation obtained by plasma bioanalysis, is crucial for developing safe and efficient drugs. Although Quantitative Whole-Body Autoradiography (QWBA) has been used for decades in the pharmaceutical industry, its cost and lack of molecular specificity make it unsuitable for early evaluation of drug distribution and metabolites.

Join Aliri Lab Director, Mathieu Gaudin, Ph.D. and customer, Hervé Giorgi Ph.D., Non-clinical Development Director at Genfit, to explore how Mass Spectrometry Imaging of whole-body mice offers an effective experimental setting for comprehensive characterization of drug pharmacokinetics at an early stage, facilitating better and faster drug candidate selection.

Key Takeaways:

• Overview of Whole-Body Pharmacokinetics (PK) and its benefits
• How this new label-free method enables decision-making by providing insights into efficacy at the site of action, anticipating potential safety concerns, and supporting better clinical candidate selection
• A customer’s perspective on the implementation of this approach in their drug development strategy

Does AI have a place in bioanalysis? We say YES!

In this session, tenured biomarker expert, Corinne Ramos, Phd, R&D Director at Aliri Bioanalysis, and Stephanie Papas-Farmer, PhD, President and Founder of BioData Solutions, share an overview of the state of AI in the drug development landscape, and real, data-backed bioanalytical applications for this powerful tool. Join us to explore how the power of AI in conjunction with genomic, proteomic, and metabolomic analyses can help predict the effectiveness of immunotherapies at an early stage in the drug development process, well before traditional methods would allow.

Watch the full-length recording below and reach out to learn how Aliri can enhance your drug development program and help you predict the effectiveness of immunotherapies earlier.